刚果民主共和国埃博拉疫情形势严峻，确诊感染者已达3200人，死亡人数超过1405人，死亡率为43.9%[1]。此次疫情由罕见的Bundibugyo病毒株引起[1]，这是刚果民主共和国第17次埃博拉疫情[1]。疫情于2026年4月下旬开始，5月15日被正式宣布[1]。病例主要集中在东北部伊图里省，该地区占近90%的感染病例[1]，目前疫情已波及5个省份[1]。
面对这一公共卫生危机，国际组织已采取行动应对。牛津大学已启动针对Bundibugyo埃博拉的实验性疫苗临床试验，首名志愿者已接种该疫苗[1]。多个疫苗候选药物目前正进行加速临床试验[1]。当前，这种致命病毒仍然缺乏特效疫苗或治疗方法[1]。
The Ebola outbreak in the Democratic Republic of the Congo continues to spread, with confirmed infections reaching 3,200 cases and deaths surpassing 1,405, representing a fatality rate of 43.9% [1]. The epidemic, caused by the rare Bundibugyo virus strain, emerged in late April 2026 and was officially announced on May 15 [1]. This marks the Democratic Republic of the Congo's seventeenth Ebola outbreak, with nearly 90 percent of cases concentrated in the northeastern Ituri Province, though five provinces in total have been affected [1].
In response to the crisis, clinical trials for an experimental vaccine have commenced, with Oxford University administering the first dose to a volunteer [1]. Multiple vaccine candidates are undergoing accelerated clinical testing as authorities race to develop protection against this outbreak. Currently, no specific vaccine or proven treatment exists for the Bundibugyo strain, underscoring the urgency of these trials [1]. The outbreak occurs against a sobering backdrop: Ebola deaths across Africa over the past 50 years have exceeded 15,000 [1].